Skip to main content

Table 16 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS, for the subgroup in Belgium

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

  EQ-5D-3L at 6 months (mean) EQ-5D-3L at 12 months (mean) Difference between 12 and 6 months EQ-5D-3L (95% CI) Effect size (Cohen’s D)a n % reporting 3L score increase
3L-VAS       
 Improved 0.82 0.84 0.02 (− 0.05 to 0.09) 0.25 6 33
 No change 0.80 0.77 − 0.02 (− 0.11 to 0.06) − 0.12 32 25
 Worsened 0.80 0.77 − 0.02 (0.10 to 0.04) − 0.13 20 20
  EQ-5D-5L at 6 months (mean) EQ-5D-5L at 12 months (mean) Difference between 12 and 6 months EQ-5D-5L (95% CI) Effect size (Cohen’s D) n % reporting 5L score increase
5L-VAS
 Improved 0.70 0.70 0.00 (− 0.15 to 0.15) − 0.01 9 33
 No change 0.80 0.78 − 0.02 (− 0.07 to 0.01) − 0.17 29 41
 Worsened 0.78 0.74 − 0.03 (− 0.12 to 0.05) − 0.18 20 30
  1. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
\